A multicenter phase II study of S-1 plus ramucirumab as first-line treatment in elderly patients with advanced/recurrent gastric cancer (KSCC1701).

Hiroo Katsuya,Koichi Suyama,Kazuma Kobayashi,Naoki Izawa,Yoshikazu Uenosono,Qingjiang Hu,Tetsuya Kusumoto,Hajime Otsu,Hiroyuki Orita,Hirofumi Kawanaka,Kazunori Shibao,Satoshi Koga,Mototsugu Shimokawa,Akitaka Makiyama,Hiroshi Saeki,Eiji Oki,Hideo Baba,Masaki Mori

A multicenter phase II study of S-1 plus ramucirumab as first-line treatment in elderly patients with advanced/recurrent gastric cancer (KSCC1701).

2021

Hiroo Katsuya
Koichi Suyama
Kazuma Kobayashi
Naoki Izawa
Yoshikazu Uenosono
Qingjiang Hu
Tetsuya Kusumoto
Hajime Otsu
Hiroyuki Orita
Hirofumi Kawanaka
Kazunori Shibao
Satoshi Koga
Mototsugu Shimokawa
Akitaka Makiyama
Hiroshi Saeki
Eiji Oki
Hideo Baba
Masaki Mori

4043Background: Elderly patients are often intolerable in the combination with cytotoxic agents. Therapy with S-1 alone is a key option for initial chemotherapy for Japanese elderly patients with u...

Keywords:

Recurrent gastric cancer
Medicine
Chemotherapy
Oncology
Ramucirumab
Internal medicine
first line treatment
Phases of clinical research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations